Skip to main content
Displaying 1 - 12 of 15
Display:
12
24
48
Immune-Mediated and Cholestatic Diseases
5
CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
5
CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
5
CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
5
CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
5
CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion" - EASL Congress 2023
View
Immune-Mediated and Cholestatic Diseases
3
CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024
View
Immune-Mediated and Cholestatic Diseases
3
CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024
View
Immune-Mediated and Cholestatic Diseases
3
CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024
View
Immune-Mediated and Cholestatic Diseases
7
CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024
View
Immune-Mediated and Cholestatic Diseases
7
CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024
View
Immune-Mediated and Cholestatic Diseases
7
CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024
View
Immune-Mediated and Cholestatic Diseases
7
CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024
View
Pagination
Current page
1
Page
2
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy